Dementia in Parkinson's disease: Case report

2011 ◽  
Vol 26 (S2) ◽  
pp. 846-846
Author(s):  
S.G. Oliveira ◽  
S.M. Pereira ◽  
J. Mendes
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Report ◽  
Psychiatric Hospitalization ◽  
Psychological Symptoms ◽  
Neuropsychiatric Symptoms ◽  
Diagnostic Testing ◽  
Visual Hallucinations ◽  
Psychomotor Agitation ◽  
Disease Case

IntroductionParkinson's disease (PD) dementia is a rapidly growing global health problem. Dementia in PD is often accompanied with neuropsychiatric manifestations, such as depression, insomnia, visual hallucinations and psychomotor agitation, which need psychiatric attention.ObjectivesThe authors’ aim is to report a case of a 76-year-old female suffering from PD who was admitted to the psychiatric yard exhibiting neuropsychiatric symptoms. A literature's review about PD dementia was also made.Case reportPatient had one psychiatric hospitalization at age 41, due to depressive symptoms. PD diagnose was made at age 65 and initially responded well to levodopa. Over the subsequent years, motor fluctuations and dyskinesias as well as autonomic, cognitive and psychological symptoms gradually developed. At 75 years, patient's family stated that she had been more forgetful, impulsive, showing signs of anxiety and dysphoria. She was hospitalized exhibiting psychomotor agitation, disorientation, insomnia and mainly nocturnal visual hallucinations with persons. Diagnostic testing included: cranial tomography which showed mild generalized atrophy but no other structural cause of her symptoms; laboratory tests with B12, folic acid, thyroid function; syphilis detection test and examinations of serum and urine were normal. The MMSE scored 19. Attention deficits and constructional apraxia were present in clock drawing test. Treatment was initiated with memantine and a low dose of quetiapine. She was discharged after 20 days with improvement of neuropsychiatric symptoms.ConclusionsEarly diagnosis and treatment of dementia in PD may prevent psychiatric hospitalization and avoid patient's and family's distress.

FP41-TH-03 Homozygous PARK7 mutation in Parkinson's disease: case report of two brothers

2009 ◽  
Vol 285 ◽  
pp. S122-S123
Author(s):  
H. Apaydin ◽  
S. Ozekmekci ◽  
D. Uluduz ◽  
Y. Hatano ◽  
Y. Mizuno ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Report ◽  
Disease Case

Hand deformity in Parkinson’s disease: case report

2004 ◽  
Vol 25 (7) ◽  
pp. 548-549 ◽  
Author(s):  
Ece Aydoğ ◽  
Emel Ekşioğlu ◽  
Aytül Çakci ◽  
Özge Yilmaz
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Report ◽  
Disease Case ◽  
Hand Deformity

Pisa syndrome without neuroleptic exposure in a patient with Parkinson's disease: Case report

2006 ◽  
Vol 21 (2) ◽  
pp. 270-273 ◽  
Author(s):  
Mattia Gambarin ◽  
Angelo Antonini ◽  
Giuseppe Moretto ◽  
Paolo Bovi ◽  
Silvia Romito ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Report ◽  
Pisa Syndrome ◽  
Disease Case

3 The dopaminergic balancing act: a literature review of a novel COMT inhibitor opicapone with a focus on the risk of visual hallucinations

2020 ◽  
Vol 91 (8) ◽  
pp. e9.2-e9
Author(s):  
Richard Cole ◽  
Romi Saha
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Literature Review ◽  
Observational Studies ◽  
Neuropsychiatric Symptoms ◽  
Psychiatric History ◽  
Visual Hallucinations ◽  
Post Hoc Analysis ◽  
Comt Inhibitor ◽  
Post Hoc

AimsParkinson’s Disease (PD) medications are well-evidenced for improving motor symptoms. However, often a balancing act is required to ameliorate positive neuropsychiatric symptoms, such as visual hallucinations (VH). Opicapone, a novel COMT inhibitor, has been shown by BIPARK-1 and BIPARK-2 studies to improve wearing-off phenomena but little is known about associated neuropsychiatric symptoms. The aim of this literature review was to investigate any association between opicapone and VH.MethodsA literature review was undertaken on the 18th July 2019 using PubMed, Ovid (using key resources of Embase, Ovid MEDLINE, Global Health and PsycINFO), Web of Science and Scopus. The search terms used were ‘Parkinson’s Disease’ and ‘Opicapone’. The search included full-texts, abstracts, conference abstracts and posters.ResultsThe initial search produced 398 articles; 391 were excluded. Of the 7 articles reviewed there were two randomised controlled trials (RCTs) (BIPARK-1 and -2), two observational studies, two post-hoc analyses of BIPARK-1 and -2, and one retrospective analysis. BIPARK-1 reported VH in 1% of the entacapone group, 8% opicapone 25 mg group and 4% of the opicapone 50 mg group. BIPARK-2 did not report on VH in their randomised phased and reported VH in 0.8% of opicapone patients in their open-label phase but without specifying the associated dose.Chaudhuri et al.’s (2018) post-hoc analysis of BIPARK-1 reported VH in 8% of COMT- naive patients given opicapone, vs. 1% of those given entacapone. Lees et al.’s (2019) post-hoc analysis of BIPARK-1 & -2 reported VH in 4.6% of patients receiving opicapone who were ≥70 years old, vs 0.6% in those younger. Gandor et al.’s (2018) prospective observational study reported VH in 14.8% of patients given opicapone.ConclusionsSeveral factors limit the conclusions drawn about the risk of VH in patients taking opicapone. The RCTs were designed and powered to assess ‘on-off’ phenomena and didn’t include patients >65 or with a psychiatric history. This also limits their post-hoc analyses’ generalisability. The more ‘real-world’ observational studies were small and only available in abstract form with limited details. Lees et al.’s (2019) post-hoc analysis nevertheless reported a higher incidence of VH in the older age group, which is concordant with known risk factors for neuropsychiatric adverse events. Further investigation is required, focusing on older patients and those with a psychiatric history or cognitive impairment.

scholarly journals The Rolex sign - first manifestation of Parkinson's disease: case report

2000 ◽  
Vol 58 (3A) ◽  
pp. 724-725 ◽  
Author(s):  
HÉLIO A. G. TEIVE ◽  
DANIEL S. SÁ
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Report ◽  
Initial Manifestation ◽  
Disease Case

We describe a patient whose initial manifestation of Parkinson's disease was a malfunctioning of a self-winding wristwatch secondary to bradykinesia of his left arm. Andrade and Ferraz reported this sign in 1996, suggesting that it be called the Rolex sign.

Management of visual hallucinations in dementia and Parkinson’s disease

2018 ◽  
Vol 31 (06) ◽  
pp. 815-836 ◽  
Author(s):  
Peter Swann ◽  
John T. O’Brien
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scales ◽  
Neuropsychiatric Symptoms ◽  
Functional Decline ◽  
Evidence Base ◽  
Psychotic Symptoms ◽  
Common Symptom ◽  
Visual Hallucinations

ABSTRACTObjectives:Visual hallucinations are a common symptom in dementia and Parkinson’s disease and have been associated with greater cognitive and functional decline, but optimal management strategies are unclear. We review the frequency and pathogenesis of visual hallucinations in dementia and Parkinson’s disease and examine the evidence base for their management.Design:We undertook a systematic review of the visual hallucinations in dementia, searching studies published between January 1980 and July 2017 using PubMed with the search terms visual hallucinations AND review AND (dementia OR parkinson*).Results:We found 645 articles and screened them for relevance, finally including 89 papers (11 meta-analyses, 34 randomized controlled trials, six other trials and a number of relevant review articles). Only six of the trials reported visual hallucination outcomes separately from other neuropsychiatric symptoms.Conclusions:Atypical antipsychotics were frequently studied, but with the exception of clozapine in Parkinson’s disease dementia, results were equivocal. There was some evidence that acetylcholinesterase inhibitors may help visual hallucinations. Overall, effect sizes for most treatments were small and there were few studies with long term follow up. Treatments need to be carefully weighed up with the risks and reviewed often, and many patients improved without treatment. There is a lack of data regarding visual hallucinations due to the grouping of psychotic symptoms together in commonly used rating scales. The lack of a specific rating scales, or analyzable items within other scales, for visual hallucinations, limited efficacy of current and small evidence base with short follow up are important areas for future studies to address.

Pregnancy in Parkinson’s disease: case report and discussion

2008 ◽  
Vol 8 (12) ◽  
pp. 1799-1805 ◽  
Author(s):  
Bradley J Robottom ◽  
Roger J Mullins ◽  
Lisa M Shulman
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Case Report ◽  
Disease Case
Sign in / Sign up

Export Citation Format

Share Document